Gonococcal Infections Gonococcal Infections
Conditions
Interventions
Group B meningococcal vaccine Bexsero will be administered on the date of enrollment in the study, with a second dose 4 weeks later. Sexually transmitted disease testing will be performed every 3 mont
C570015
Sponsors
Aoki Takahiro
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1)Adult MSM aged 18 years or older who are regular attendees at ACC or SH outpatient clinics (2)Patients with a history of bacterial STI (syphilis, gonorrhea, or chlamydia) in the past 2 years (3) Those who have given written consent to participate in the study.
Exclusion criteria
Exclusion criteria: (1)Those who are allergic to meningococcal B vaccine Bexsero (2)Patients with contraindications to intramuscular injection of the vaccine due to abnormalities in the blood coagulation system, etc. (3)Patients with a history of Bexsero administration (4)gonococcal infection positive at screening (5) Other conditions that make participation in the study inappropriate for the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preventive efficacy of group B meningococcal vaccine Bexsero in preventing gonococcal infections. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of Bexsero prophylaxis on other bacterial STIs. VE in the presence of overlapping other bacterial STIs. VE in the presence of HIV infection. Collecting Bexsero adverse events. | — |
Contacts
Public ContactTakahiro Aoki
National Center for Global Health and Medicine
Outcome results
None listed